GIST Secondary KIT — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardImmunotherapy & Targeted TherapyGIST Secondary KITSCE Medical Oncology

A 62-year-old man with GIST on imatinib develops progressive disease with a secondary KIT exon 17 D816V mutation. What is the treatment?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Avapritinib — type I KIT inhibitor with specific activity against activation-loop mutations (exons 17/18 including D816V)

Secondary KIT resistance: ATP-binding (exons 13/14) → sunitinib. Activation-loop (exons 17/18, D816V) → avapritinib/ripretinib. Molecular profiling at progression guides TKI sequencing.

Reference: ESMO 2024 GIST; NICE Avapritinib